Journal of Bone and Mineral Research
You selected: Journal of Bone and Mineral Research
In a study of patients with Paget’s disease of bone—a common skeletal disorder that can lead to bone deformity, fractures, osteoarthritis, and bone pain—long-term intensive bisphosphonate therapy conferred no clinical benefit over giving bisphosphonates only when patients felt bone pain.
Previous case reports in patients with osteogenesis imperfecta (OI) have suggested that treatment with bisphosphonates, which are commonly prescribed for osteoporosis, may be associated with atypical femur fractures. A new retrospective study of 119 children with OI indicates that such fractures are related to the severity of OI rather than to bisphosphonate use, however.
Abaloparatide, a selective activator of the parathyroid hormone receptor, has recently been shown to reduce fractures in postmenopausal women with osteoporosis. Now new research shows that abaloparatide increases bone mass in rats whose ovaries have been removed by stimulating bone formation, without effects on bone resorption.
A recent analysis of results from a randomized controlled clinical trial indicates that abaloparatide-SC, a novel therapy for osteoporosis, provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.
Consistently watching high levels of television during childhood and adolescence were linked with lower peak bone mass at age 20 years in a recent study.
In 2005, the National Institute for Health and Care Excellence (NICE) in England and Wales provided new guidance on the use of anti-osteoporosis therapies for the prevention of additional fractures in patients who had experienced osteoporotic fractures, which was followed by market authorization of a generic form of alendronic acid.
A new report by a Task force of the American Society for Bone and Mineral Research provides guidance on the use of bisphosphonates, which are the most commonly used medications for osteoporosis.
Following a decade of steady growth, use of bisphosphonates—medications that are effective for treating osteoporosis—declined in the United States by more than 50% from 2008 to 2012.
Despite reports that people with osteoporosis have an increased risk of dying prematurely, a new study has found that life expectancy of newly diagnosed and treated osteoporosis patients is in excess of 15 years in women below the age of 75 and in men below the age of 60.
The term “sarcopenia” is most often used to describe age-related loss in muscle mass and strength, and it is commonly considered analogous to osteoporosis. Yet unlike osteoporosis, which can be diagnosed based on widely accepted clinical criteria, sarcopenia is not recognized as a clinical condition even though it can impair physical function and contribute to disability, falls, and hospitalizations.
The daily rhythm of bone turnover is likely important for normal bone health, and recent research suggests that sleep apnea may be an unrecognized cause of some cases of osteoporosis. Sleep apnea’s effects on sleep duration and quality, oxygen levels, inflammation, and other aspects of health may have a variety of impacts on bone metabolism.
A review of more than a decade's worth of research on osteonecrosis of the jaw--when the bone in the jaw is exposed and begins to starve from a lack of blood--points to an increased risk for patients taking certain drugs for osteoporosis, anticancer drugs or glucocorticoids, those undergoing dental surgery, and people with poor oral hygiene, chronic inflammation, diabetes, or ill-fitting dentures.
From: Journal of Bone and Mineral Research
Use of vitamin D supplements during pregnancy has long been a matter of concern but now researchers writing in the Journal of Bone and Mineral Research report that even a high supplementation amount in healthy pregnant women was safe and effective in raising circulating vitamin D to a level thought by some to be optimal.